Revenue Performance - Total revenue for the three months ended September 30, 2025, was $241.0 million, a 32.2% increase from $182.3 million in the same period of 2024[148] - For the nine months ended September 30, 2025, total revenue was $395.3 million, reflecting a 23.3% increase from $320.7 million in the same period of 2024[148] - Ticket revenue reached $172,543,000 for the nine months ended September 30, 2025, up 26.1% from $134,243,000 in 2024[152] Attractions and Hospitality Performance - Attractions revenue increased by $31.7 million (32.6%) in Q3 2025, driven by a 21.9% increase in visitors and an 8.7% rise in revenue per visitor[148] - Hospitality revenue rose by $26.7 million (33.7%) in Q3 2025, primarily due to a 35.0% increase in Revenue per Available Room (RevPAR) and a 5.2% increase in available room nights[149] - The number of visitors to attractions reached 1,980,681 in Q3 2025, a 21.9% increase compared to 1,195,856 in Q3 2024[150] - RevPAR for hospitality properties was $280.56 in Q3 2025, a 35.0% increase from $207.85 in Q3 2024[150] - The effective ticket price for attractions was $50.69 in Q3 2025, reflecting a 9.3% increase from $46.37 in Q3 2024[150] - Total visitors increased to 3,575,285 for the nine months ended September 30, 2025, a 14.2% increase compared to 2,588,952 in the same period of 2024[152] Expenses and Operating Costs - Operating expenses increased by 26.3% to $86,592,000 for the three months ended September 30, 2025, primarily due to higher variable costs[154] - Selling, general, and administrative expenses rose by 20.0% to $17,445,000 for the three months ended September 30, 2025, driven by transaction-related costs[156] Cash Flow and Liquidity - Net cash provided by operating activities attributable to continuing operations increased by $40.2 million to $99.783 million for the nine months ended September 30, 2025, compared to $59.566 million in the prior year[168] - Net cash used in investing activities attributable to continuing operations increased by $107.9 million to $145.077 million for the nine months ended September 30, 2025, primarily due to cash paid for the acquisition of Tabacón[169] - Net cash provided by financing activities attributable to continuing operations increased by $108.4 million to $33.953 million for the nine months ended September 30, 2025, compared to a net cash used of $74.469 million in the prior year[170] - As of September 30, 2025, total available liquidity was $274,409,000, significantly up from $49,702,000 at the end of 2024[161] Foreign Currency and Liabilities - The company recorded cumulative unrealized foreign currency translation losses of $51.5 million as of September 30, 2025, down from $62.9 million as of December 31, 2024[174] - The company had long-term contractual liabilities denominated in nonfunctional currencies amounting to $46.4 million as of September 30, 2025[176] - The company experienced an unrealized foreign currency translation gain of $15.5 million during the nine months ended September 30, 2025, compared to a loss of $7.7 million in the prior year[174] Capital Expenditures and Investments - The company has planned capital expenditures of approximately $71 million to $76 million for 2025, including $38 million to $43 million on growth projects[166] - Capital expenditures increased to $44.097 million for the nine months ended September 30, 2025, compared to $40.659 million in the prior year[169] Corporate Developments - The company completed the sale of the GES Business for an aggregate purchase price of $535 million on December 31, 2024[143] - The acquisition of Tabacón Thermal Resort & Spa on July 1, 2025, is expected to generate more evenly distributed revenue throughout the year[146] - The company began trading under the new NYSE ticker symbol PRSU on January 2, 2025, following the transformation into Pursuit Attractions and Hospitality, Inc.[144] Tax and Gains - The effective tax rate decreased to 16.8% for the three months ended September 30, 2025, compared to 17.2% in the same period of 2024[159] - The company recorded a gain of $4.2 million related to business interruption proceeds from the Jasper wildfires during the three months ended September 30, 2025[157]

Exhibit 99.1 Carlsmed®Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., November 6, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30 ...

Clinical Trials and Product Development - 89% of evaluable frontline AML patients achieved remission with mipletamig in combination therapy across two trials, including 100% remission in Cohort 3 of the RAINIER trial[3] - Aptevo introduced its first trispecific T-cell engagers, APVO451 and APVO452, expanding its oncology portfolio to five CRIS-7-derived CD3-targeting molecules[4] - Aptevo's pipeline now includes six preclinical candidates targeting various solid tumors, leveraging its proprietary ADAPTIR and ADAPTIR-FLEX platforms[18] Financial Performance - The company raised $18.7 million in Q3 2025 and an additional $4.1 million post-quarter, extending its cash runway into Q4 2026[10] - Cash and cash equivalents totaled $21.1 million as of September 30, 2025, increasing to $25.2 million after additional fundraising[10] - Research and development expenses rose to $4.0 million in Q3 2025, up from $3.1 million in Q3 2024, primarily due to increased mipletamig and employee costs[11] - General and administrative expenses increased to $3.6 million in Q3 2025, compared to $2.1 million in Q3 2024, mainly due to higher employee costs[12] - Aptevo reported a net loss of $7.5 million or $2.23 per share for Q3 2025, compared to a net loss of $5.1 million or $357.86 per share in Q3 2024[12] - The total assets of Aptevo increased to $26.996 million as of September 30, 2025, from $15.591 million at the end of 2024[15] - The company’s accumulated deficit reached $269.2 million as of September 30, 2025, compared to $247.6 million at the end of 2024[15] Risks and Uncertainties - Aptevo's actual results may differ materially from forward-looking statements due to various risks, including clinical trial uncertainties and regulatory changes[21] - The company faces known and unknown risks that could impact the availability or commercial potential of its product candidates[21] - Macroeconomic conditions such as rising inflation, interest rates, and decreased consumer confidence are potential factors affecting Aptevo's performance[21] - The ongoing geopolitical risks, including the war between Russia and Ukraine, may also influence the company's business environment[21] - Aptevo does not assume any obligation to update forward-looking statements unless required by law[21]

Revenue Performance - Total revenue for Q3 2025 was $634.4 million, a decrease of 0.7% year-over-year; on a constant currency basis, revenue decreased by 1.2%[6] - Total annual recurring revenue (Total ARR) was $2.536 billion, down 1.7% year-over-year; on a constant currency basis, ARR decreased by 1.5%[6] - Paying users totaled 18.07 million, compared to 18.24 million in the same period last year; average revenue per paying user was $139.07[6] Profitability Metrics - GAAP operating margin improved to 27.5%, up from 20.0% year-over-year; Non-GAAP operating margin increased to 41.1% from 36.2%[6] - GAAP net income was $123.8 million, compared to $106.7 million for the same period last year; Non-GAAP net income was $196.7 million, up from $190.4 million[6] - The company reported a GAAP diluted net income per share of $0.47, compared to $0.34 in the same period last year; Non-GAAP diluted net income per share was $0.74, up from $0.60[6] Cash Flow and Liquidity - Net cash provided by operating activities was $302.1 million, an increase from $274.2 million year-over-year; free cash flow was $293.7 million, up from $270.1 million[6] - Cash, cash equivalents, and short-term investments totaled $925.3 million at the end of the quarter[6] - Cash, cash equivalents, and restricted cash at the end of the period were $764.2 million, a decrease from $1,360.5 million at the beginning of the period[16] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $716.4 million, up from $680.3 million in the same period of 2024, reflecting a growth of about 5%[16] - Free cash flow for the three months ended September 30, 2025, was $293.7 million, up from $270.1 million in the same period of 2024, representing a growth of 8.5%[28] - Unlevered free cash flow for the nine months ended September 30, 2025, was $765.0 million, compared to $661.1 million for the same period in 2024, reflecting a growth of 15.7%[28] Expenses and Investments - Research and development expenses for the three months ended September 30, 2025, were $182.3 million, with a research and development margin of 28.7%[18] - Research and development expenses totaled $545.1 million, with a margin of 28.9%[22] - Sales and marketing expenses were $271.3 million, leading to a margin of 14.4%[22] - General and administrative expenses amounted to $170.2 million, with a margin of 9.0%[22] - The company incurred stock-based compensation expenses of $78.6 million for the three months ended September 30, 2025[16] - Capital expenditures for the three months ended September 30, 2025, were $8.4 million, up from $4.1 million in the same period of 2024[28] Balance Sheet and Assets - Total assets decreased from $3,325.2 million as of December 31, 2024, to $2,795.8 million as of September 30, 2025, representing a decline of approximately 16%[14] - Total current liabilities increased significantly from $1,210.8 million to $1,903.2 million, marking an increase of approximately 57%[14] - Total liabilities increased from $4,077.6 million to $4,327.0 million, indicating a rise of approximately 6%[14] Operational Efficiency - Operating margin for the three months ended September 30, 2025, was 27.5%, reflecting a significant increase in operational efficiency[18] - Income from operations for the nine months ended September 30, 2025, was $526.9 million, reflecting an operating margin of 28.0%[22] - The operating margin for the nine months ended September 30, 2025, was 41.4%[22] Strategic Initiatives - The company launched a self-serve version of Dash, providing access to an AI assistant and search engine for its 575,000 paying businesses[3] - The company is focused on sustainable growth and improving retention in its core business[3] - The company disclosed that it has provided non-GAAP financial measures to give investors additional insights into its performance, including revenue growth on a constant currency basis[29] - Management believes that free cash flow is an important indicator of liquidity and provides useful information regarding cash generated from operations[32] - Non-GAAP measures are used by management to evaluate financial performance and are reconciled to GAAP measures to mitigate limitations[33] Workforce and Restructuring - Total cash payments related to workforce reduction amounted to $13.2 million during the nine months ended September 30, 2025[28] - The company has made payments related to lease termination amounting to $36.0 million during the nine months ended September 30, 2025[28]

Financial Performance - Total revenues for the three months ended September 30, 2025, were $10,882,000, an increase of 4.4% compared to $10,418,000 for the same period in 2024[12] - Net income for the three months ended September 30, 2025, was $8,780,000, representing a 153.5% increase from $3,468,000 in the prior year[12] - Net income for the nine months ended September 30, 2025, was $16,855,000, compared to $7,616,000 for the same period in 2024, representing a 121% increase[17] - Net cash provided by operating activities increased to $16,987,000 for the nine months ended September 30, 2025, from $16,160,000 in 2024, reflecting a growth of 5.1%[17] - The company reported a net loss before taxes of $660,000 for Q3 2025, compared to a loss of $892,000 in Q3 2024[68] - The company reported a net income of $8,780,000 for the three months ended September 30, 2025, compared to a net loss of $3,468,000 for the same period in 2024, representing a significant turnaround[112] Assets and Liabilities - Total assets decreased to $289,362,000 as of September 30, 2025, from $332,235,000 as of December 31, 2024, reflecting a decline of approximately 12.9%[10] - Total stockholders' equity as of September 30, 2025, was $254,206,000, down from $288,690,000 at the end of 2024, indicating a decrease of about 11.9%[10] - Total liabilities decreased to $35,156,000 as of September 30, 2025, from $43,545,000 as of December 31, 2024, a reduction of approximately 19.3%[10] - The carrying value of finance receivables, net, was $245,396,000 as of September 30, 2025, remaining unchanged from its fair value[105] Credit Losses and Impairments - The provision for credit losses for the three months ended September 30, 2025, was a benefit of $931,000, compared to a provision of $1,385,000 in the same period of 2024[12] - The provision for credit losses for the nine months ended September 30, 2025, was a benefit of $1.59 million, compared to a provision of $10.78 million for the same period in 2024[49] - The company incurred a loss on impairment of intangible assets amounting to $209,000 for the three months ended September 30, 2025[12] - The company reported a loss on impairment of intangible assets of $209,000 for the nine months ended September 30, 2025, compared to $5,771,000 in 2024[17] Cash Flow and Dividends - The company reported a cash dividend of $4.00 per share, totaling $49,078,000[14] - Cash dividends paid amounted to $49,078,000 in 2025, while there were no dividends paid in 2024[19] - The company had cash and cash equivalents of $10,206,000 at the end of the period, down from $17,178,000 at the end of the previous year[19] Finance Receivables - The company’s investment in finance receivables increased to $28,500,000 in 2025 from $17,736,000 in 2024, representing a 61% increase[19] - Total gross finance receivables as of September 30, 2025, amounted to $253.136 million, with term loans contributing $241.634 million and royalties $11.502 million[61] - Nonaccrual finance receivables totaled $11.50 million as of September 30, 2025, compared to $14.83 million as of December 31, 2024, a decrease of 22.5%[52] - The company collected $2.5 million on nonaccrual finance receivables for the nine months ended September 30, 2025, compared to $2.6 million for the same period in 2024[52] Employee and Operational Changes - The company had 9 full-time employees as of September 30, 2025, following the sale of substantially all assets of the Pharmaceutical Development segment[22] Debt and Financing - The Company entered into a revolving credit facility with an initial maximum principal amount of $45 million, with the option to increase it by up to $80 million[72] - The Company issued $30.0 million of 9.00% Senior Notes due 2027, with total net proceeds of approximately $30.6 million after deducting costs[78] - The outstanding balance of the 2027 Senior Notes as of September 30, 2025, was $32.969 million, net of debt issuance costs[79] - The Company recognized $0.9 million and $2.7 million of interest expense related to the Notes for the three and nine months ended September 30, 2025, respectively[81] Market and Economic Conditions - The company has a finance receivables portfolio primarily based on floating interest rates, which exposes it to interest rate risk[160] - Inflation may impact partner companies, potentially affecting their ability to repay loans, which could adversely affect the company's investment valuations[162] - The company does not currently engage in interest rate hedging activities, which may expose it to risks from interest rate fluctuations[161] Revenue Recognition - The company’s pharmaceutical development segment generated fee revenue from a collaboration agreement with AptarGroup, Inc., contributing to its revenue recognition[26] - The Company recognized total contract revenue of $2,153,000 for the nine months ended September 30, 2025, compared to $1,711,000 for the same period in 2024, indicating a year-over-year increase of approximately 25.8%[108]

Revenue Performance - Total revenue for the three months ended September 30, 2025, was $223.6 million, a 122.4% increase compared to $100.5 million in the same period of 2024[151]. - Service revenue reached $190.0 million for the three months ended September 30, 2025, up 132.1% from $81.9 million in the prior-year period, primarily due to the acquisition of Satcom Direct[152]. - Equipment revenue increased to $33.6 million for the three months ended September 30, 2025, representing an 80.1% rise from $18.7 million in the same period of 2024, also attributed to the Satcom Direct acquisition[153]. Active Connections - The number of ATG aircraft online as of September 30, 2025, was 6,529, compared to 7,016 in the prior year, indicating a decrease in active connections[139]. - Average monthly connectivity service revenue per ATG aircraft online was $3,407 for the three months ended September 30, 2025, slightly down from $3,497 in the same period of 2024[139]. - The company expects service revenue to decline in the near term due to a decrease in ATG services sold, but anticipates future growth as more aircraft come online with Gogo 5G and Gogo Galileo[154]. Operating Income and Expenses - Operating income for the three months ended September 30, 2025, was $28.7 million, compared to $19.1 million in the same period of 2024[149]. - Total operating expenses for the three months ended September 30, 2025, were $194.8 million, up from $81.5 million in the prior-year period[149]. - The company reported a net loss of $1.9 million for the three months ended September 30, 2025, compared to a net income of $10.6 million in the same period of 2024[149]. Cost Analysis - Cost of service revenue increased 380.8% to $91.6 million for the three months ended September 30, 2025, compared to $19.1 million in the prior year[155]. - Cost of equipment revenue rose 104.6% to $31.0 million for the three months ended September 30, 2025, compared to $15.2 million in the prior year[156]. - Engineering, design, and development expenses increased 60.7% to $15.7 million for the three months ended September 30, 2025, compared to $9.8 million in the prior year[158]. - Sales and marketing expenses increased 57.5% to $13.5 million for the three months ended September 30, 2025, compared to $8.6 million in the prior year[160]. - General and administrative expenses increased 11.8% to $27.9 million for the three months ended September 30, 2025, compared to $24.9 million in the prior year[162]. - Depreciation and amortization expense increased 278.9% to $15.2 million for the three months ended September 30, 2025, compared to $4.0 million in the prior year[164]. - Total other expense increased to $29.3 million for the three months ended September 30, 2025, compared to $6.9 million in the prior year[167]. Tax and Cash Flow - The effective income tax rate for the three months ended September 30, 2025, was (242.8)%, compared to 12.5% in the prior year[169]. - Free Cash Flow is defined as net cash provided by operating activities, plus proceeds from the FCC Reimbursement Program, less purchases of property and equipment[179]. - For the nine months ended September 30, 2025, net cash provided by operating activities was $115.987 million, compared to $79.740 million for the same period in 2024, representing a year-over-year increase of approximately 45%[195]. - Free cash flow for the nine months ended September 30, 2025, was $94.126 million, compared to $81.515 million for the same period in 2024, indicating an increase of about 15.5%[1]. Capital Expenditures and Debt - Capital expenditures for the nine months ended September 30, 2025, were $34.732 million, significantly higher than $18.894 million for the same period in 2024, marking an increase of approximately 83.9%[200]. - The company announced a share repurchase program allowing for the repurchase of up to $50 million of common stock, with approximately $12.1 million remaining available as of September 30, 2025[186]. - The company prepaid $100 million of the outstanding principal amount of the 2021 Term Loan Facility on May 3, 2023, satisfying the required amortization payments for the remaining term[189]. - As of September 30, 2025, cash and cash equivalents at the end of the period were $133.572 million, down from $176.678 million at the end of the same period in 2024[183]. Interest Expense and Risk Management - Interest expense for the nine months ended September 30, 2025, was $50.650 million, compared to $26.193 million for the same period in 2024, reflecting an increase of approximately 93.5%[1]. - The company expects its cash and cash equivalents, along with cash flows from operating activities, to be sufficient to meet its cash requirements for at least the next twelve months[184]. - Capital expenditures are expected to increase in the near term due to the LTE network build-out related to the FCC Reimbursement Program, but this increase will be partially offset by reimbursements from the FCC[201]. - The company has minimal interest rate risk, as a 10% decrease in the average interest rate on its portfolio would have resulted in immaterial reductions in interest income for the three- and nine-month periods ended September 30, 2025 and 2024[209]. Investment Policy and Inflation - The primary objective of the company's investment policy is to preserve capital and maintain liquidity while limiting concentration and counterparty risk[205]. - The company has not used derivative financial instruments for speculation or trading purposes, focusing instead on preserving capital for funding operations[205]. - Inflation has not had a material effect on the company's results of operations, although future impacts cannot be ruled out[210].

Financial Performance - Q3 2025 revenue was $45.9 million, representing a 14% sequential growth[4] - Adjusted EBITDA for Q3 2025 was $5.8 million, up 22% sequentially, with GAAP Net Income of $1.4 million[4] - GAAP gross margin for Q3 2025 was 41.6%, marking the third consecutive quarter with gross margin exceeding 40%[4] - Total revenues for Q3 2025 were $45,893 million, a decrease of 15.1% compared to $54,032 million in Q3 2024[21] - Mobile solutions revenue reached $16,037 million, while fixed wireless access solutions generated $17,650 million, showing significant growth from $9,723 million in the previous year[21] - Operating income for Q3 2025 was $2,155 million, compared to $1,016 million in Q3 2024, indicating a positive trend in operational efficiency[21] - Net income attributable to common stockholders for Q3 2025 was $529 million, a decrease from $8,142 million in Q3 2024[21] - GAAP income from continuing operations for Q3 2025 was $1,432 million, a significant increase from $507 million in Q2 2025[27] - Non-GAAP net income for Q3 2025 reached $2,839 million, up from $2,161 million in Q2 2025, reflecting a 31.3% quarter-over-quarter growth[27] - Adjusted EBITDA for Q3 2025 was $5,751 million, compared to $4,726 million in Q2 2025, indicating a 21.7% increase[27] Guidance and Projections - Q4 2025 financial guidance projects revenue in the range of $45.0 million to $48.0 million and Adjusted EBITDA between $4.0 million and $5.0 million[8] Cash and Assets - Cash and cash equivalents decreased to $14,559 million as of September 30, 2025, down from $39,596 million at the end of 2024[23] - Total current assets were $56,985 million, a decline from $72,900 million as of December 31, 2024[23] - The company reported a net cash used in operating activities of $4,763 million for the nine months ended September 30, 2025, compared to $47,710 million in the same period of 2024[25] Expenses and Liabilities - Research and development expenses for Q3 2025 were $4,878 million, slightly down from $5,176 million in Q3 2024[21] - The total liabilities decreased to $93,531 million as of September 30, 2025, from $112,857 million at the end of 2024[23] - Share-based compensation expense increased to $1,850 million in Q3 2025 from $1,654 million in Q2 2025[27] - Interest expense decreased to $885 million in Q3 2025 from $933 million in Q2 2025, showing a reduction of 5.1%[27] - Depreciation and amortization expenses rose to $2,189 million in Q3 2025, compared to $1,792 million in Q2 2025[27] Leadership and Strategic Developments - A new Tier-1 U.S. carrier customer was secured, with FWA shipments expected to begin late in Q4 2025 and mobile shipments in Q1 2026[4] - The FX4200 enterprise FWA solution was launched, expanding into larger enterprises and creating new market paths via MSPs and MSOs[4] - The company appointed Donna Johnson as CMO and Vishal Donthireddy as CTO, enhancing its leadership team[4] Share Performance - GAAP loss per diluted share improved to $0.03 in Q3 2025 from a loss of $0.03 in Q2 2025[27] - Non-GAAP net income per diluted share for Q3 2025 was $0.12, up from $0.08 in Q2 2025, representing a 50% increase[27] - The number of shares used in computing GAAP income per diluted share was 15,522,042 in Q3 2025, an increase from 15,023,832 in Q2 2025[27] Other Financial Impacts - The company reported a gain on debt restructurings of $16,541 million in Q4 2024, which significantly impacted the financial results[27]

Exhibit 99.1 OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the ...

-- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next generation PI3Ka pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 Exhibit 99.1 OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update -- First patients ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...